Bibliografía

1. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-99
2. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-59
3. Lohse N, Hansen A, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95
4. Losina E, Schackman B, Sadownik S, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009;49:1570-78
5. DeeksS. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011;62:141-55.
6. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998 May 2;351(9112):1328.
7. Mary-Krause M, Partisani M, Simon A, Costagliola D. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV infected men. Presented at the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001.
8. Holmberg S, Moorman A, Williamson J, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
9. Currier J, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune DeficSyndr 2003;33:506-12.
10. Klein D, Hurley L, Quesenberry C, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune DeficSyndr 2002;30:471-7.
11. Bozzette S, Ake C, Tam H, Chang S, Louis T. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
12. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
13. Islam F, Wu J, Jansson J, Wilson D. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012;13:453-68.
14. Triant V, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J ClinEndocrinolMetab 2007;92:2506-12.
15. Niaura R, Shadel W, Morrow K, Tashima K, Flanigan T, Abrams D. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis 2000; 31:808-12.
16. Centers for Disease Control and Prevention. Vital Signs: Current Cigarette Smoking Among Adults Aged ≥ 18 Years – United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59(35):1135-1140.
17. DiFranzia J, Guerrera M. Alcoholism and smoking. J Stud Alcohol 1990;51:130–5.
18. Hughes J. Treatment of smoking cessation in smokers with past alcohol/drug problems. J Subst Abuse Treat 1993; 10:181–7.
19. Samet J, Horton N, et al. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcoholism: Clinical & Experimental Research 2004;28(4):572-577.
20. Hwang L, Ross M, et al. Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers. Clin Infect Dis. 2000;31(4): 920-926.
21. Chaisson R, Bacchetti P, et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989;261(4):561-565.
22. Lai S, et al. Human immunodeficiency virus 1 infection, cocaine, and coronary calcification. Archives of Internal Medicine 2005;165(6):690-695.
23. Sherman K, Rouster S, Chung R, Rajicic N. Hepatitis C virus prevalence among patients coinfected with human immunodeficiency virus: a cross-sectional analysis of the U.S. Adult AIDS Clinical Trials Group. CID 2002;34:831-837.
24. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. CID 2001;32:492-497.
25. Freiberg M, Chang C, Skanderson M, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C.CircCardiovascQual Outcomes. 2011;4:425-32.
26. Riddler S, Smit E, Cole S, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289(22):2978-82.
27. Grunfeld C, Pang M,Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Journal of Clinical Endocrinology and Metabolism1992;74(5):1045–1052.
28. HaugaardS,Andersen O, Pedersen S, et al. Tumor necrosis factor α is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism2006;55(2):175–182.
29. Mujawar Z, Rose H, Morrow M, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoSBiol 2006;4(11):e365.
30. Francisci D, Giannini S, Baldelli F, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009; 23:589.
31. Baker J, Duprez D, Rapkin J, et al. Untreated HIV infection and large and small artery elasticity. J Acquir Immune DeficSyndr 2009; 52:25.
32. Neuhaus J, Jacobs D, Baker J, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788-95.
33. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008;214:231–41.
34. Brenchley J, Price D, Schacker T, et al.Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2000;12:1365–71.
35. Naeger D, Martin J, Sinclair E, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010;5:e88-86.
36. Hunt P, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIVRNA levels in the absence of therapy. J Infect Dis 2008 Jan 1;197(1):126-33.
37. Hsue P, Hunt P, Schnell A, et a. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009;23(9):1059-67.
38. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010;170:1228-38.
39. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;;356(17):1723-35.
40. Worm S, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Infect Dis 2010;201:318-30.
41. Dube M, Shen C, Greenwald M, Mather K. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis 2008; 47(4):567–574.
42. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients — association with antiretroviraltherapy: results from the DAD study. AIDS 2003;17:1179-93.
43. El-Sadr W, Reiss P, De Wit S. Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age and lipid changes. 12th Conference on Retroviruses and Opportunistic Infections; February 2005; Boston, USA. (Abstract 42).
44. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9.
45. Brown T, Cole S, Li X, et al. Prevalence and incidence of pre-diabetes and diabetes in the Multicenter AIDS Cohort Study. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8–11, 2004:73. abstract.
46. Dube M, Vanderluitgaren J, Leffler C, et al. Effect of indinavir (IND) monotherapy on endothelial function in men without HIV infection. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 24–28, 2002. abstract.
47. Fleischman A, Johnsen S, Systrom D, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J PhysiolEndocrinolMetab 2007;292(6):E1666-73.
48. Choi A, Vittinghoff E, Deeks S, et al. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011 Jun 19;25(10):1289-98.
49. vanLeth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1(1):e19.
50. Sankatsing R, Franssen R, Hassink E, et al. Nevirapine increases highdensity lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. ArteriosclerThrombVascBiol 2009; 29(9):1336–1341.
51. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998 May 7;12(7):F51-8.
52. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005 Jan 6;352(1):48-62.
53. Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003;21(7):1377-82.
54. El-Sadr W, Lundgren J, Neaton J, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006 Nov 30;355(22):2283-96.
55. Phillips A, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. AntivirTher 2008;13(2):177-87.
56. Baker J, Henry W, Neaton J. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. CurrOpin HIV AIDS. 2009;4(3):176-82.
57. Law M, Friis-Møller N, El-Sadr W, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7:218.
58. Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. EurJ CardiovascPrevRehabil2010;17(5):491-501.
59. Blaha M, Bansal S, Rouf R, et al. A practical "ABCDE" approach to the metabolic syndrome. Mayo ClinProc 2008;83(8):932-41.
60. Post W. Predicting and preventing cardiovascular disease in HIV-infected patients. Top Antivir Med. 2011;19(5):169-73.
61. Lundgren J, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9(2):72-81.
62. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012 (http://www.aidsinfo.nih.gov)
63. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult

Treatment Panel III). JAMA 2001;285:2486-97.

1. Lo J. Dyslipidemia and lipid management in HIV-infected patients. CurrOpinEndocrinol Diabetes Obes 2011;18:144-7.
2. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIVinfected patients. PLoS One 2011;6(7):e21843.
3. Soriano V, García-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J AntimicrobChemother 2008;61:200-5.
4. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284:472-477.
5. Grinspoon S, Grunfeld C, Kotler D, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008;118(2):198-210.